JATT II Acquisition ^{Priced, Nasdaq: JATT}

We are a blank check company. While we may pursue an initial business combination in any business or industry, we intend to focus our search on healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences. In particular, we intend to seek businesses that can benefit from the clinical, scientific, operational, strategic and capital markets experience of our management team and board of directors and, in many cases, from access to the public markets as a means of funding continued development, executing strategic transactions and increasing visibility with investors and potential partners. We expect to focus particularly, though not exclusively, on businesses applying data-driven approaches, including machine learning, computational biology, structure-based drug design and related technologies, to improve the therapeutic discovery and development process. Our management team is led by Dr. Someit Sidhu, our Chairman and Chief Executive Officer, and Mr. Nicholas Fernandez, our Chief Financial Officer, each of whom has significant experience building, operating and investing in the life sciences and medical technology sectors globally.